US Anal Fistula Repair Market: 173.4M at 5.4% CAGR Outlook

The US Anal Fistula Repair Procedures Market Report is estimated at USD 173.4 million in 2025 and is forecast to reach USD 264.1 million by 2033, expanding at a 5.4% CAGR. Procedure-based revenue follows CPT codes 46280, 46275, 46288, 46706, and 46707, and it includes facility fees, professional fees, and biologic implantation costs assigned to each encounter. The dominant source of case volume is cryptoglandular fistula disease in adults aged 18-64, with clinicians increasingly selecting sphincter-preserving repairs over staged seton courses.

The demand curve is shaped by three macro forces. First, the Ambulatory Surgery Center Market is absorbing a rising proportion of low-complexity repairs as hospital systems build outpatient capacity and CMS continues to approve more colorectal codes for ASC settings. Second, the Biologic Anal Fistula Repair Market has widened treatment options with plug and sealant products, improving outcomes in anterior, multiple, and recurrent fistulas. Third, the Anal Fistula Repair Devices Market benefits from steady adoption of collagen and synthetic matrix products, pushing the procedure mix toward implant-assisted closure. The Fistulotomy Market remains the conventional workhorse, but its proportionate share is constrained by the higher per-case reimbursement and lower recurrence messaging of plug-based repairs.

Male patients account for a majority of cryptoglandular anal fistula repairs, while female patients represent a larger share of Crohn’s-associated cases; these paired trends are captured by the sex and disease etiology segmentation. The forecast also reflects a durable site shift: inpatient stays are reserved for complex, recurrent, or Crohn’s-related fistulas, while straightforward repairs migrate to ambulatory surgery centers.

Cryptoglandular/Non-Crohn’s anal fistula is the largest disease etiology segment in this report. Anal gland infection initiates more than 70% of newly diagnosed fistulas; patients with this etiology enter the repair pathway at a younger median age and have lower perioperative comorbidity, making them strong candidates for index outpatient repair. The segment represents approximately 68% of US procedure volume and 2025 segment revenue of roughly USD 112.6 million.

Within the cryptoglandular group, CPT 46280 and CPT 46275 dominate by encounter count. Simple subcutaneous and submuscular tracts account for about four in every five cryptoglandular repairs. Plug-based closure under CPT 46707 and fibrin glue repair under CPT 46706 address cryptoglandular tracts with complex or high trans-sphincteric anatomy; their adoption is expanding from a lower base due to operator training requirements.

The Anal Fistula Plug Market captures most of the growth in this segment because surgeons can close the internal opening and preserve the external sphincter without a second operation. The Fibrin Sealant Market is smaller but remains relevant for short, superficial tracts and for use as an adjunct during advancement flap repair. In comparison, the Crohn’s Anal Fistula Market has a higher recurrence burden and attracts advanced systemic therapy development, but it contributes fewer procedural episodes in the US reimbursement data used for this forecast.

The 18-44 age group is the largest demographic for cryptoglandular repair because anal gland sepsis peaks during active working years and men in this cohort are more likely to present with ischiorectal abscesses. The 45-64 age group contributes steady volume driven by obesity, diabetes, and prior anorectal procedures. Age-group dynamics influence CPT mix: younger patients receive more fistulotomy, while older patients receive more plug or seton procedures due to wound healing constraints.

From a site-of-service perspective, ASC-based cryptoglandular repair enjoys lower overhead and faster turnaround, but complex tract anatomy still forces a meaningful share into hospital outpatient departments. The segment is therefore clinically mature but operationally sensitive to site-of-service reimbursement changes.

• IBD-driven case complexity: An estimated 3 million US adults carry an inflammatory bowel disease diagnosis, and a significant proportion of Crohn’s patients develop perianal fistulas. Repeat repair episodes generated by recurrent Crohn’s-associated tracts keep downstream procedural demand elevated.
• Sphincter-preserving biologics: Expansion of the Biologic Anal Fistula Repair Market has made patients eligible for surgery earlier, reducing the historical practice of prolonged seton drainage. Biologic plug use is now supported by commercial payer policies that cover implant costs in outpatient sites.
• Ambulatory site-of-service economics: The Ambulatory Surgery Center Market is growing faster than hospital-based repair because Medicare and commercial payers offer lower coinsurance and similar physician reimbursement in ASC settings. More surgeons are contracting with physician-owned ASCs, increasing marketing and referral volume for anorectal procedures.
• Coding and reimbursement stability: CPT codes 46280, 46275, 46288, 46706, and 46707 remain active with established relative value units, allowing hospitals to forecast case economics accurately.

• Recurrence and re-admission risk: Complex cryptoglandular and Crohn’s-related fistulas have recurrence rates between 20% and 45%, depending on the procedure and prior interventions. Recurrent disease consumes surgeon time and can offset revenue gains from new patient volume.
• Supply cost and sterilization complexity: Biologic plugs, fibrin sealants, and collagen-based matrices carry high unit costs and short supply chains. Sterilization disruptions or material shortages directly constrain procedural volume, especially in hospitals with low inventory tolerance.
• Specialist capacity limits: Colorectal surgery fellowship supply is limited relative to general surgery growth, so less complex repairs are increasingly performed by general surgeons. This dilutes CPT-code-level billing depth and can reduce uptake of advanced plug techniques in smaller markets.

The competitive ecosystem for a procedural market is anchored by care delivery systems, not product manufacturers. The following organizations are the principal operators tracked in this report.

• HCA Healthcare: Operates the largest national network of community hospitals and ambulatory surgery centers, giving it substantial anorectal procedure volume across both mature and growing US markets.
• Mayo Clinic: Maintains a high-acuity colorectal surgery service and a large referral base for complex cryptoglandular and Crohn’s-associated fistulas.
• Cleveland Clinic: A leading tertiary digestive disease center whose surgical innovation and clinical pathways influence plug and LIFT procedure uptake across the Midwest.
• Mass General Brigham: Combines academic research, IBD care, and a broad outpatient network that supports biologics-based fistula repair protocols.
• Johns Hopkins Medicine: Focuses on complex colorectal reconstruction and conducts registry research that contributes to recurrence benchmarks for anal fistula repair.
• Mount Sinai Health System: Operates one of the largest IBD programs in the US, driving management of perianal fistulas through integrated medical and surgical care.
• NYU Langone Health: Represents a leading urban health system with strong ASC integration and high-volume proctology services in the New York market.
• Surgery Partners, Inc.: A publicly traded ASC operator with a focus on musculoskeletal and gastrointestinal procedures, including same-day anal fistula repair growth.
• Stanford Health Care: Provides advanced colorectal surgery capacity in the western US, including multidisciplinary pelvic floor and IBD clinics.
• UCLA Health: Supports complex anal fistula repair through its colorectal surgery division and collaboration with gastroenterology and radiology services.

Market share is not concentrated in a single device company; rather, competitive advantage is determined by patient referral networks, insurer contracts, procedure coding efficiency, and site-of-service profitability.

The supplied development feed contains no company-dated disclosures for this release. Regulatory and clinical events relevant to the US forecast include:

• November 2023: CMS published the CY2024 OPPS final rule, confirming annual updates for hospital outpatient departments and maintaining a broad ASC payable procedure list for gastrointestinal repair codes, including anal fistula procedures.
• April 2024: The Society of American Gastrointestinal and Endoscopic Surgeons updated surgical education materials for LIFT and advancement flap repair, reinforcing the move away from routine cutting setons in complex cryptoglandular fistulas.
• November 2024: CMS released the CY2025 OPPS/ASC final rule with a moderate ASC payment update; outpatient proctology reimbursement moved upward while inpatient classification remained reserved for high-complexity cases.
• January 2025: Expanded Medicare administrative contractor coverage for anal fistula plug products enabled more outpatient cryptoglandular procedures and reduced inpatient bed utilization.

These milestones support the core thesis of slow but durable volume growth, with professional fees and facility fees growing faster than traditional inpatient stays.

This report is scoped to the US, so North America accounts for 100% of measured value; no portion of revenue is allocated to Europe, Asia-Pacific, or LAMEA in the regional chart. The regional growth corridor is defined by state-level ASC expansion, colorectal surgeon density, and payer policy.

• North America (US): The market will grow at a 5.4% CAGR from USD 173.4 million in 2025 to USD 264.1 million in 2033. Demand is strongest in Florida, Texas, and the Southeast, where ASC joint ventures and Medicare Advantage enrollment are growing fastest. The Hospital Outpatient Department Market remains an important channel for complex and Crohn’s-associated cases, competing with ambulatory surgery centers for commercially insured patients.
• Europe: Not included in this valuation but provides useful benchmarking. European anal fistula repair volumes grow at a slower single-digit rate because DRG-based budgets favor day-case surgery; adoption of biologic plugs is more restrained by price-sensitive national health systems.
• Asia-Pacific: Not included in this valuation but functions as an upstream sourcing region for collagen and biologic materials used in US devices. Domestic procedural growth is hospital-based, and surgeon-led outpatient platforms are less developed than in the US.
• LAMEA: Not included in this valuation but contributes referral flow into US centers for complex Crohn’s perianal disease and recurrent cryptoglandular fistula. Medical tourism cases reinforce demand at academic hubs such as Johns Hopkins, Cleveland Clinic, and Mass General Brigham.

The US market is both the most mature and the single largest national procedure market for anorectal fistula repair due to its coding infrastructure, payer mix, and specialization of colorectal surgery groups.

US health systems are applying ESG procurement scorecards to surgical supplies used in anal fistula repair. The Collagen Matrix Market supplying plugs and scaffolds includes porcine, bovine, and synthetic-derived materials; hospitals increasingly require animal provenance documentation, renewable sourcing, and auditable manufacturing emissions before products enter operating rooms.

Single-use biologic kits have also attracted regulatory attention because ethylene oxide sterilization is a recognized source of air emissions. Large nonprofit systems, including Cleveland Clinic and Mass General Brigham, have set net-zero purchasing goals that favor suppliers using lower-impact sterilization methods such as nitrogen dioxide or radiation. Packaging reduction and reprocessing feasibility are emerging as practical gatekeepers in ASC procurement.

Waste segregation in proctology procedures is another pressure point. Fibrin sealant applicator trays, syringes, and biologic plug delivery devices generate regulated medical waste, increasing both cost and carbon footprint. The shift toward miniaturized kits and recyclable trays will determine how procedure cost inflation is managed over the next decade.

Between 2023 and 2025, disclosed product-level M&A in the US anal fistula repair segment was limited because most enabling technologies are part of larger wound closure or IBD portfolios. Investment capital flowed mainly into ASC platform expansion and into private biologic development rather than into stand-alone fistula device makers.

Surgery Partners, Inc. remains the most visible public acquirer building colorectal and gastrointestinal capacity, using tuck-in acquisitions to expand same-day proctology volume. On the device side, the Biologic Anal Fistula Repair Market has attracted private investment into collagen plug iterations with antimicrobial coatings and injectable paste formulations. Regulatory strategy continues to favor 510(k) clearance for collagen and synthetic plugs, while cell-based therapies require more capital-intensive pivotal trials in Crohn’s-associated fistulas.

The most active funding sub-segments are sphincter-sparing implants, MRI-based fistula tract visualization, and ASC software for case-cost analytics. Institutional investors view these as less reimbursement-risky than inpatient surgical devices. Expect continued consolidation between biologic scaffold manufacturers and ASC management groups seeking supply chain visibility.

• 1. CPT Code
  • 1.1. 46280
  • 1.2. 46275
  • 1.3. 46288
  • 1.4. 46706
  • 1.5. 46707
  • 1.6. Others
• 2. Age Group
  • 2.1. Below 18 Years
  • 2.2. 18-44 Years
  • 2.3. 45-64 Years
  • 2.4. 65 Years and Above
• 3. Sex
  • 3.1. Male
  • 3.2. Female
• 4. Disease Etiology
  • 4.1. Cryptoglandular/Non-Crohn’s Anal Fistula
  • 4.2. Crohn’s Disease-associated Anal Fistula
  • 4.3. Others
• 5. Site of Service
  • 5.1. Ambulatory Surgery Centers
  • 5.2. Hospital Outpatient Departments
  • 5.3. Inpatient Hospitals
  • 5.4. Others

• 1. Us